NCT05568979View on ClinicalTrials.gov

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2022/23

CompletedOBSERVATIONAL
Enrollment

1,001

Participants

Timeline

Start Date

October 6, 2022

Primary Completion Date

November 29, 2022

Study Completion Date

November 29, 2022

Conditions
Influenza (Healthy Volunteers)
Interventions
BIOLOGICAL

Quadrivalent Influenza Vaccine

Intramuscular or subcutaneous administration

BIOLOGICAL

High-Dose Quadrivalent Influenza Vaccine

Intramuscular administration

Trial Locations (15)

10117

Investigational Site Number : 2760011, Berlin

20100

Investigational Site Number : 2-2-001, Turku

26100

Investigational Site Number : 2-2-006, Rauma

33100

Investigational Site Number : 2-2-003, Tampere

36037

Investigational Site Number : 2760002, Fulda

40100

Investigational Site Number : 2-2-005, Jyväskylä

40470

Investigational Site Number : 2760004, Düsseldorf

60329

Investigational Site Number : 2760007, Frankfurt am Main

70100

Investigational Site Number : 2-2-004, Kuopio

78166

Investigational Site Number : 2760001, Donaueschingen

82152

Investigational Site Number : 2760009, Martinsried

90530

Investigational Site Number : 2760008, Wendelstein

97506

Investigational Site Number : 2760003, Grafenrheinfeld

99444

Investigational Site Number : 2760005, Blankenhain

00180

Investigational Site Number : 2-2-002, Helsinki

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY